Clinical Trials in the USA / NCT07525791
Active, not recruiting Phase 1

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791 · tracked via the Priya Life Science USA tracker
Phase
Phase 1
Started
2026-04-07
Last updated
2026-09-30

Condition(s) studied

OverweightObesity

Investigational drug(s) / intervention(s)

NNC0662-0419 →Oral contraceptive →Acetaminophen →

NNC0662-0419: Once-weekly subcutaneous NNC0662-0419 will be administered using a pen injector

Oral contraceptive: An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally.

Acetaminophen: A single dose of acetaminophen will be administered orally.

Study summary

The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living with overweight or obesity. There are 3 study treatments in this study, participants will get all of the treatments, NNC0662-0419 the treatment being tested, Altavera a type of birth control pill, Acetaminophen a common type of mild painkiller.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female (sex assigned at birth) of non-childbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body weight more than or equal to (≥) 60.0 kilogram (kg). * Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Use of any medication containing glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), or amylin receptor agonism before screening. * Any contraindications for the use of the oral contraception used in the study according to the Altavera Product Information. * Use of hormone replacement therapy within 28 days before screening or intention to initiate treatment with hormone replacement therapy during the study. * Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation. * Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator. * History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Altasciences Clinical Kansas, Inc. Overland Park Kansas

On this site

📄 Tylenol (acetaminophen) drug profile →

More Novo Nordisk A/S trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07525791 on ClinicalTrials.gov ↗ ← All trials in the USA